In this study, patients who have undergone or will undergo a transcatheter edge-to-edge repair (TEER) for tricuspid valve regurgitation (TR) will be followed up for 5 years. The goal of this prospective and retrospective, observational, non-randomized, multicenter registry is to confirm that TEER is a feasible, safe and effective treatment option for TR and to evaluate the long-term efficacy and safety of TEER. The main endpoints are: * Change in tricuspid regurgitation grade: number of patients with a reduction in tricuspid regurgitation score by at least one grade * Composite of major adverse event: number of patients with composite of major adverse event (cardiovascular mortality, acute kidney injury, myocardial infarction, stroke or TIA, coronary revascularization, new onset AF or ventricular arrhythmia)
Study Type
OBSERVATIONAL
Enrollment
120
Minimally invasive transcatheter-based edge-to-edge repair technique for tricuspid regurgitation
Number of patients with a reduction in tricuspid regurgitation score by at least one grade
Number of patients with a reduction in tricuspid regurgitation score by at least one grade 30 days post-procedure
Time frame: 30 days
Composite of major adverse event
Number of patients with composite of major adverse event (cardiovascular mortality, acute kidney injury, myocardial infarction, stroke or TIA, coronary revascularization, new onset AF or ventricular arrhythmia)
Time frame: 1 year
Number of patients with a reduction in tricuspid regurgitation score by at least one grade at 6 months post-procedure
Number of patients with a reduction in tricuspid regurgitation score by at least one grade 6 months post-procedure
Time frame: 6 months
Number of patients with a reduction in tricuspid regurgitation score by at least one grade 1 year post-procedure
Number of patients with a reduction in tricuspid regurgitation score by at least one grade 1 year post-procedure
Time frame: 1 year
Number of patients with a reduction in tricuspid regurgitation score by at least one grade 2 years post-procedure
Number of patients with a reduction in tricuspid regurgitation score by at least one grade 2 years post-procedure
Time frame: 2 years
Number of patients with a reduction in tricuspid regurgitation score by at least one grade 3 years post-procedure
Number of patients with a reduction in tricuspid regurgitation score by at least one grade 3 years post-procedure
Time frame: 3 years
Number of patients with a reduction in tricuspid regurgitation score by at least one grade 4 years post-procedure
Number of patients with a reduction in tricuspid regurgitation score by at least one grade 4 years post-procedure
Time frame: 4 years
Number of patients with a reduction in tricuspid regurgitation score by at least one grade 5 years post-procedure
Number of patients with a reduction in tricuspid regurgitation score by at least one grade 5 years post-procedure
Time frame: 5 years
Composite of major adverse event at discharge
Number of patients with composite of major adverse event (cardiovascular mortality, acute kidney injury, myocardial infarction, stroke or TIA, coronary revascularization, new onset AF or ventricular arrhythmia) at discharge
Time frame: 5 days
Composite of major adverse event at 5 years post-procedure
Number of patients with composite of major adverse event (cardiovascular mortality, acute kidney injury, myocardial infarction, stroke or TIA, coronary revascularization, new onset AF or ventricular arrhythmia) 5 years post-procedure
Time frame: 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.